Knee Osteoarthritis With Stromal Vascular Fraction Cells

Treatment of Knee Osteoarthritis With Stromal Vascular Fraction Cells: 10-Years Follow-up

This is an interventional study to treat knees osteoarthritis (KOA) with adipose-derived stromal vascular fraction cell components in sixteen subjects with either unilateral or bilateral symptomatic Kellgren Lawence Grade 3 KOA by intra-articular injection of knees. Later, subjects were followed for safety out and potential benefits.

A prospective, open-label interventional study was conducted to assess safety and evidence of clinical response to administration of intra-articular SVF in 16 patients with symptomatic, radiographic Kellgren Lawence grade 3 KOA. Approximately 55.5 million SVF cells were administered via intra-articular injection into each of the 29 knees; asymptomatic knees remained untreated. Subjects were followed for safety out to six months. Potential benefit was measured using the Knee Injury Osteoarthritis Outcome Scores (KOOS) at baseline (pre-treatment), at 3- and 6-months post-treatment, and then subsequently at 10 years.

Inclusion Criteria:

• Radiologically documented Kellgren Lawence grade 3 (moderate) KOA;
• Knee pain rated greater than 4/10 on the linear pain scale;
• Previous treatment history with anti-inflammatory medications or corticosteroid injections

Exclusion Criteria:

• Corticosteroid injection within 3 months prior to SVF treatment
• Taking anticoagulants prior to SVF treatment